Vikasol solution in ampoules: instructions for use
This drug is designed to quickly normalize the process of blood coagulation. Vikasol is considered an artificially produced vitamin K analogue. Takes part in the process of formation of prothrombin. If there is a lack of vitamin K in the human body, then hemorrhagic manifestations occur.
Release form and composition
Vikasol carton contains 10 pieces of ampoules with a volume of 1 ml. The content of the active component - Vicasol - 1 ml 10 mg. Excipients are represented by water for injection, sodium metabisulfite and hydrochloric acid. Each vial contains information about the production series and the expiration date. This data is also on the secondary packaging. In addition to the ampoules inside the container there is a detailed instruction.
Indications for use
Vikasol is usually prescribed by the attending physician for such conditions:
- jaundice due to the delayed entry of bile into the liver;
- acute hepatitis;
- a variety of bleeding from both internal organs and capillary (before and after surgical procedures);
- ulcers of the digestive tract, accompanied by bleeding of varying severity;
- hemorrhages under the mucous membranes and skin that occur with a decrease in platelet count in the blood test (thrombocytopenic purpura);
- bleeding from the nose and rectum persistent nature (with hemorrhoids);
- pregnancy in the third trimester (for the prevention of bleeding in the newborn) - the appointment is carried out individually by a doctor;
- radiation sickness;
- hemorrhagic bleeding in newborns;
- prolonged uterine juvenile and premenopausal bleeding;
- pulmonary tuberculosis , accompanied by bleeding;
- various septic diseases with bleeding;
- use of anticoagulants that are considered vitamin K antagonists.
Vikasol is ineffective in the treatment of Verlgof's disease and hemophilia.
The drug should not be administered with increased blood clotting, with thromboembolism, hemolytic disease in newborns, as well as during individual sensitivities as to the main component, and to any excipient.
Caution is needed during pregnancy, deficiency of glucose-6-phosphate dehydrogenase and liver failure.
Dosing and Administration
Vikasol is used only by intramuscular injection. The dose for an adult should be from 10 to 15 mg of Vicasol single dose. The daily dose for this age group is 30 mg.
Use in children varies significantly with age. Dosage in newborns and children up to 12 months is 0.4 mg per kilogram of body weight per day. From the year to 2 years, the daily dose is 6 mg. From 3 to 4 years old - 8 mg per 24 hours. From the age of 5 years and up to the 9 - year period, the daily dose is 10 mg. From 10 to 14 years, the dosage of Vikasol is 15 mg per day. The drug is prescribed from 2 to 3 times in 24 hours. The course of therapy is usually 3 - 4 days. It is allowed to repeat the course after a 4 - day break. The selection of the duration of treatment is determined by the doctor.
The prothrombin index is determined 3 hours after drug administration Vikasol. If this indicator does not correspond to the norm, then the introduction is carried out again, but taking into account the fact that the daily dose cannot exceed 40 mg of Vicasol.
If it is necessary to conduct serious surgical procedures with the likelihood of a strong parenchymal bleeding, prescribe the drug 2 or 3 days before the operation.
Patients of the older age group are more sensitive to Vikasol. At selection of a dosage for them it is necessary to be guided by the lower boundaries of the recommended values.
The drug can cause such unwanted side effects:
- occurrence of pain and swelling at the injection site. When you re-enter sometimes spots appear on the skin;
- skin rash. May be accompanied by erythema, pruritus and urticaria;
- hemolysis in newborns with congenital deficiency of glucose-6-phosphate dehydrogenase;
- hemolytic anemia;
- the appearance of dizziness;
- a decrease in blood pressure;
- change in taste;
- sudden sweating;
- the occurrence of tachycardia.
Symptoms that can develop with an accidental overdose: hyperbilirubinemia, toxicosis with convulsions (a symptom more typical of children), hyperprothrombinemia. When these manifestations of overdose are prescribed anticoagulants and stop the use of Vikasol.
The drug is completely ineffective in the treatment of Verlgof's disease or hemophilia. During the third trimester of pregnancy, the prophylactic administration of Vicasol is impractical due to the low permeability of the placenta for him. It is recommended that prophylaxis of hemorrhagic disease in newborn babies should not be carried out by Vikasol, but by phytomenadione, which less frequently provokes the development of adverse symptoms.
If the bleeding is extensive and severe, then treatment with Vikasol alone will not be sufficient. Blood transfusion required. The earliest effect after drug administration always develops only 8 hours after injection.
If long-term treatment with Vikasol is to be taken, then control over clotting indicators is performed regularly.
Vikasol in no way affects the anticoagulant capacity of heparin. Significantly weakens the effectiveness of indirect anticoagulants. Increasing the dosage of vitamin K is required with the parallel use of antibiotics, quinine, high doses of salicylates, quinidine and antibacterial sulfonamides.
Use with drugs that can provoke hemolytic crisis in patients suffering from deficiency of glucose-6-phosphate dehydrogenase, increases the likelihood of adverse events.
The need for Vicasol in the treatment of warfarin is evaluated additionally.
Menadione and vitamin K can be attributed to Vicasol's analogues.
Terms and conditions of storage
Ampoules should be stored only in dark places away from children with temperature indicators not exceeding 25 degrees.
Vikasol ampoules price
Vikasol solution for injection 1% - 60-80 rubles.